



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## Melanin concentrating hormone in peripheral circulation in the human

**Citation for published version:**

Naufahu, J, Alzaid, F, Fiuza Brito, M, Doslikova, B, Valencia, TM, Cunliffe, A & Murray, JF 2017, 'Melanin concentrating hormone in peripheral circulation in the human', *Journal of Endocrinology*.  
<https://doi.org/10.1530/JOE-16-0240>

**Digital Object Identifier (DOI):**

[10.1530/JOE-16-0240](https://doi.org/10.1530/JOE-16-0240)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Journal of Endocrinology

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



1 TITLE: Melanin concentrating hormone in peripheral circulation in the human

2

3 AUTHORS: J. Naufahu, F. Alzaid<sup>1</sup>, M. Fiuza Brito<sup>2</sup>, B. Doslikova<sup>3</sup>, T. Valencia<sup>4</sup>, A.

4 Cunliffe<sup>5</sup>, J.F. Murray<sup>6</sup>

5

6 ADDRESS: Faculty of Science and Technology, University of Westminster, 115 New

7 Cavendish Street, London, W1W 6UW, United Kingdom

8 1. Current address: Sorbonne Universités, Université Pierre et Marie-Curie;

9 INSERM, Centre de Recherches des Cordeliers, UMRS 1138, Paris, 75006, France

10 2. Current address: Royal Brompton & Harefield NHS Foundation Trust, Sydney

11 Street, London, SW3 6NP, United Kingdom

12 3. Current address: Department of Pharmacology, University of Alberta, 9-36

13 MSB, T6G 2H7, Canada

14 4. Current address: Regulus Therapeutics Inc., 10614 Science Center Drive

15 San Diego, CA 92121, United States of America

16 5. Current address: Department of Applied Sciences, London South Bank

17 University, 103 Borough Road, London, SE1 0AA, United Kingdom

18 6. Current address: Centre for Integrative Physiology, Hugh Robson Building,

19 George Square, University of Edinburgh, Edinburgh, EH8 9XD, United Kingdom

20

21 CORRESPONDING AUTHOR and REQUESTS FOR REPRINTS:

22 Joanne F. Murray

23 Edinburgh Medical School: Biomedical Sciences

24 Centre for Integrative Physiology

25 Hugh Robson Building

26 George Square

27 University of Edinburgh

28 Edinburgh, EH8 9XD

29 United Kingdom

30 jmurra19@exseed.ed.ac.uk

31 T: +44 (0)131 651 1711

32

33 SHORT TITLE: MCH in peripheral circulation in the human

34 KEY WORDS: circulating melanin concentrating hormone, radioimmunoassay,  
35 human, metabolism, leptin

36 Word count: 4597

37

38 **ABSTRACT**

39 Melanin concentrating hormone (MCH) is a hypothalamic neuropeptide with a well-  
40 characterised role in energy homeostasis and emergent roles in diverse physiologic  
41 functions such as arousal, mood and reproduction. Work to date has predominantly  
42 focused on its hypothalamic functions using animal models however little attention  
43 has been paid to its role in circulation in humans. The aims of this study were to a)  
44 develop a radioimmunoassay for the detection of MCH in human plasma; b)  
45 establish reference ranges for circulating MCH; and c) characterize the pattern of  
46 expression of circulating MCH in humans. A sensitive and specific RIA was  
47 developed and cross-validated by RP-HPLC and MS. The effective range was 19.5–  
48 1248 pg MCH/ml. Blood samples from 231 subjects were taken to establish a  
49 reference range of 19.5–55.4 pg/ml for fasting MCH concentrations. There were no  
50 significant differences between male and female fasting MCH concentrations  
51 however there were correlations between MCH concentrations and BMI in males and  
52 females with excess fat ( $p < 0.001$  and  $p = 0.020$ ) and between MCH concentrations  
53 and fat mass in females with excess fat ( $p = 0.038$ ). Plasma MCH concentrations rose  
54 significantly after feeding in a group of older individuals ( $n = 50$ , males  $p = 0.006$ ,  
55 females  $p = 0.023$ ). There were no robust significant correlations between fasting or  
56 post-prandial MCH and resting metabolic rate, plasma glucose, insulin or leptin  
57 concentrations although there were correlations between circulating MCH and leptin  
58 concentrations in older individuals ( $p = 0.029$ ). These results indicate that the role of  
59 circulating MCH may not be reflective of its regulatory hypothalamic role.

60 Word Count: 248

61

62

63

64 **INTRODUCTION**

65 Melanin concentrating hormone (MCH), is an orexigenic neuropeptide; rodent  
66 studies indicate it has multiple and diverse physiologic functions including a key role  
67 in the central control of energy metabolism. Intracerebroventricular (ICV)  
68 administration of MCH results in hyperphagia and increased adiposity (Qu *et al.*,  
69 1996; Gomori *et al.*, 2002; Santollo and Eckel, 2008), whilst decreased availability of  
70 hypothalamic MCH results in hyper- or hypophagia accompanied by reduced body  
71 weight and fat mass depending on whether a pharmacological or genetic model is  
72 used (Marsh *et al.*, 2002; Segal-Lieberman *et al.*, 2003; Mashiko *et al.*, 2005).  
73 Ablation of functional MCH results in increased energy expenditure via increased  
74 metabolic rate, increased locomotor activity, or both (Shimada *et al.*, 1998; Segal-  
75 Lieberman *et al.*, 2003). MCH is expressed in the central nervous system (CNS),  
76 primarily in the rostral zona incerta/incerto-hypothalamic and the lateral hypothalamic  
77 areas (Bittencourt *et al.*, 1992; Sita *et al.*, 2007; Bittencourt, 2011). Prepro-MCH  
78 mRNA and MCH have also been reported in rodent and human peripheral tissue  
79 (Hervieu and Nahon, 1995; Verlaet *et al.*, 2002; Sandig *et al.*, 2007). Circulating  
80 MCH has been detected in both rodents (Bradley *et al.*, 2000; Stricker-Krongrad *et*  
81 *al.*, 2001; Sun *et al.*, 2004) and humans (Gavrila *et al.*, 2005; Schmidt *et al.*, 2015)  
82 however there has been published debate concerning the validity of the detection  
83 methods used in the earlier human study (Mantzoros, 2005; Waters and Krause  
84 2005). Both central and peripherally-derived MCH are implicated in glucose  
85 homeostasis (Ludwig *et al.*, 2001; Pereira-da-Silva *et al.*, 2005; Bjursell *et al.*, 2006)  
86 and there is evidence of local production of MCH in the endocrine pancreas in

87 rodents and humans (Pissios *et al.*, 2007). However the physiological role of  
88 circulating MCH remains largely unexplored at present.

89

90 The overall aim of these studies was to determine whether circulating concentrations  
91 of MCH are related to body weight regulation and metabolism by developing and  
92 validating a competitive RIA for the detection of MCH in human plasma, and  
93 conducting a cross-sectional study in order to establish reference ranges for  
94 circulating MCH. Two intervention studies were also conducted to investigate  
95 whether circulating MCH concentrations were acutely responsive to food stimuli,  
96 furthermore plasma MCH concentrations in both the fasted and fed states were  
97 examined in association with circulating glucose, insulin and leptin concentrations.  
98 Additionally, associations between circulating MCH and resting metabolic rate (RMR)  
99 were investigated.

100

## 101 **MATERIALS AND METHODS**

### 102 MCH RIA development and validation

103 *Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) and Mass*  
104 *Spectrometry (MS)*

105 RP-HPLC was conducted using a modified version of a previously described method  
106 (Maulon-Ferraille *et al.*, 2002). The optimum dilution for detection of MCH in plasma  
107 was 1:9 plasma: 0.1 N HCl (v:v). The mixture was centrifuged at 4°C and 1000 rpm  
108 for 10 minutes and the supernatant analyzed by HPLC in a RP column (C18  
109 Phenomenex, UK) with a gradient of 20–60% (0.1% trifluoroacetic acid in HPLC  
110 water: acetonitrile) for 60 minutes at a flow rate of 0.5 ml/min. Purified MCH was  
111 serially diluted and treated similarly for comparison. MCH was detected using UV

112 absorbance at 230 nm. Protein fragments obtained by RP-HPLC were subject to MS  
113 for determination of analyte mass. MS was performed by single quadropole mass  
114 spectrometric detector (Dionex MSQ Plus, Dionex Corp., Massachusetts, USA) and  
115 MS data analysed using Chromeleon LC/MS software (Dionex Corp.,  
116 Massachusetts, USA).

117

118 Blood from the same individual was collected in different vacutainers (lithium  
119 heparin, silica+gel, fluoride oxalate, EDTA and sodium citrate) to establish if there  
120 was any effect on the detection of MCH by RP-HPLC. To determine the lability of  
121 MCH in plasma, a separate blood sample was subjected to the following conditions:  
122 room temperature 1 hour; 4°C 1 hour; room temperature overnight; 4°C overnight; -  
123 20°C overnight; and -20°C before being thawed, refrozen and thawed again. The  
124 samples were processed as described above and compared with a freshly prepared  
125 sample.

126

#### 127 *RIA for MCH*

128 A double antibody RIA for MCH was developed using commercially available  
129 reagents; that is, MCH antibody (M8440: Sigma-Aldrich, UK), radiolabelled MCH  
130 (<sup>125</sup>I-MCH; NEX373010UC: PerkinElmer Inc., USA) and anti-rabbit SacCel (AA-  
131 SAC1: IDS Ltd., UK). Phosphate buffered saline with 1% bovine serum albumin  
132 (A3294: Sigma-Aldrich, UK) was used throughout. Day 1: MCH antibody (1:30,000  
133 in 100 µl) with normal rabbit serum (1:300) was added to diluted standards and  
134 unknowns and left at 4°C. Day 2: <sup>125</sup>I-MCH (10,000 cpm/100 µl) diluted in buffer  
135 supplemented with EDTA (0.025 M) was added to each tube and left at 4°C. Day 3:  
136 SacCel (solid phase anti-rabbit IgG coated cellulose suspension: IDS Ltd., Boldon,

137 UK) was added following the manufacturer's instructions; that is, 0.1 ml SacCel were  
138 added to each tube (except total counts), left for 30 minutes at room temperature  
139 and then 1 ml deionized water was added before all tubes were centrifuged at 1000  
140 rpm and 4°C for 10 min. The supernatant was aspirated and the resultant pellet was  
141 counted for 1 minute on a gamma counter. Data were analysed using AssayZap  
142 (Biosoft, Cambridge, UK).

143

144 To determine possible cross-reactivity, a series of dilution curves (range 0.1 pg–0.1  
145 mg) of biomolecules reported to have a competitive or agonistic relationship with  
146 MCH were treated as unknowns in the MCH assay. Biomolecules tested were:  
147 human atrial natriuretic peptide (ANP; A1663: Sigma-Aldrich, UK) (Hervieu *et al.*,  
148 1996); human  $\alpha$ -MSH (H1075: Bachem, Switzerland) (Barber *et al.*, 1987; Ludwig *et*  
149 *al.*, 1998); human ACTH (H1160: Bachem, Switzerland) (Baker *et al.*, 1985); and  
150 neuropeptide–E-I-MCH (NEI-MCH; H4714: Bachem, Switzerland) (Maulon-Ferraille  
151 *et al.*, 2002).

152

### 153 *Comparison between RP-HPLC and RIA*

154 Plasma samples collected in EDTA tubes were diluted with either 0.1 N HCl or buffer  
155 with EDTA (1:9 dilution) with/without purified MCH and subjected to RP-HPLC.  
156 Fractions were collected at 1 minute intervals and the aliquots analysed for MCH by  
157 RIA.

158

### 159 Circulating MCH

#### 160 *Subjects*

161 The experiments involving human subjects were approved by the University of



162 Westminster's Ethics Sub-Committee. Each subject gave full informed consent.

163 Fasting blood samples were taken from all subjects between 8 and 11.30 am.

164

165 Cross-sectional study: Fasting venous blood samples were collected from 135

166 females and 96 males. Weight to the nearest 0.1 kg, height to the nearest 0.1 cm,

167 waist and hip circumference were measured. Total fat and lean body mass were

168 measured by air displacement plethysmography (BodPod: Body Composition

169 Tracking System, Version 4.1; Life Measurement Instruments, Concord, CA, USA).

170 All venous blood samples were collected in EDTA vacutainers and plasma recovered

171 after centrifugation. Plasma was stored at -20°C until MCH concentrations were

172 determined by RIA (intra- and inter-assay CVs were 2.4% and 3.7%, respectively).

173

174 Intervention studies: Two cohorts were recruited. Cohort A) 18–30 years: 21 females

175 and 11 males. The inclusion criteria for females were: pre-menopausal (however the

176 stage of the menstrual cycle was not recorded); non-hormonal contraceptive using;

177 and a body mass index (BMI) of  $\leq 24.9$ . The inclusion criterion for males was BMI of

178  $\leq 24.9$ . Cohort B) Over 40 years: a) lean individuals (11 females and 11 males) and

179 b) those with excess body fat (13 females and 15 males). Lean (L) was defined as

180  $< 31$  % body fat in females and  $< 21$  % body fat in males. Excess body fat (E) was

181 defined as  $\geq 31$  % body fat in females and  $\geq 21$  % body fat in males (ACSM, 1996).

182 The inclusion criterion for both males and females was that they should be over 40

183 years of age. In both cohorts, those on medication(s) for chronic illness or known to

184 cause hypo- or hyperglycaemia or affect metabolic rate and females who were

185 pregnant, lactating or recently lactating were excluded.

186

187 *Protocol.* Subjects arrived after an overnight fast, anthropometric, body composition  
188 and resting metabolic rate (RMR) (Deltatrac II Metabolic Monitor, Datex  
189 Instrumentarium Corp., Helsinki, Finland) measurements were made. Fasting  
190 venous and fingerprick blood samples were obtained before subjects were fed a  
191 controlled meal of mixed macronutrient content (388 k/cal females; 510 k/cal males).  
192 Eight fingerprick samples were obtained at 15 minute intervals and 3 venous blood  
193 samples at 30, 60 and 120 minutes post meal. Plasma was recovered from the  
194 venous blood samples and stored at -20°C until assayed for MCH, leptin (HL-81HK,  
195 Millipore, USA; intra-assay CV: 8.3% at 4.9 ng/ml; 3.4% at 25.6 ng/ml) and insulin  
196 (DSL-1600, Diagnostic Systems Inc., USA; intra-assay CV: 8.3% at 4.8 µIU/ml; 6.4%  
197 at 54.6 µIU/ml). All samples for each cohort were assayed for each hormone in a  
198 single assay. The fingerprick blood samples were immediately analysed for blood  
199 glucose concentrations using the Hemocue Glucose 201+ Analyser (Hemocue AB,  
200 Sweden; intra-assay CV <1.8%).

201

#### 202 *Data and Statistical Analyses*

203 RMR: The group was sub-divided based on percentage of "Standard BMR" (Fleisch,  
204 1951). A BMR of  $\pm 10\%$  Standard is considered normal (McArdle *et al.*, 2001). The  
205 groups were Low (L)=  $\leq 89.9\%$  Standard BMR; Normal (N)=within 10% of Standard  
206 BMR; High (H)=  $\geq 110\%$  Standard BMR. RMR has been used synonymously with  
207 BMR since the only condition specific to BMR that was not met was that subjects did  
208 not sleep at the facility overnight.

209

210 Body composition: subjects were sub-divided into four groups based on the  
211 American College of Sports Medicine's body fat percentage cut-off points: male lean

212 (ML)=body fat % <21%; male excess fat (ME)=body fat % ≥21%; female lean  
213 (FL)=body fat % <31%; female excess fat (FE)=body fat % ≥31% (ACSM, 1996).  
214 Subjects were sub-divided by body composition after data collection for the cross-  
215 sectional and both intervention studies.

216

217 Inter-gender differences between anthropometric characteristics and circulating  
218 hormone concentrations were established by independent samples t-tests. A one-  
219 way between groups ANOVA with Tukey's Multiple Comparison test was conducted  
220 to determine whether there was an effect of body composition on plasma MCH  
221 concentrations. Associations between fasting plasma MCH concentrations and  
222 body composition parameters were determined by Pearson product-moment  
223 correlational analysis. Differences in pre- and post-prandial circulating hormone  
224 concentrations were assessed by paired samples t-tests. Leptin concentrations were  
225 not normally distributed and so the data were transformed using the square root  
226 before the analyses. Comparisons between circulating hormone concentrations at  
227 the four sampling time-points were assessed by repeated measures design ANOVA.  
228 When analyzing the AUC data, only individuals with data from all four blood samples  
229 were included in the analyses and hence the lower 'n' values. Data were analysed  
230 using the Statistical Package for the Social Sciences (SPSS version 16.0 for  
231 Windows; Chicago, IL, US) or Prism (Prism 5 for Mac OS X; GraphPad Software,  
232 Inc.). Statistical significance was set at  $p < 0.05$ .

233

## 234 **RESULTS**

### 235 RIA development and validation

236 The gold standard method for the detection of MCH is RP-HPLC and MS hence this  
237 method was used to demonstrate that MCH is present in plasma. Using RP-HPLC,  
238 the retention time for purified MCH was between 21 and 28 minutes (Figure 1a). It  
239 was predicted that product ions of m/z 796 and 2 of m/z 1194 would be generated  
240 specifically for MCH and these were detected at the corresponding elution times  
241 when either purified MCH or human plasma samples were analysed by MS (Figure  
242 1b). MCH was only detected by RP-HPLC and MS in samples collected in the  
243 lithium heparin, silica+gel and EDTA vacutainers. No effect of storage under the  
244 conditions described could be detected when compared to freshly prepared samples  
245 measured by RP-HPLC and MS (data not shown). Purified MCH, plasma and buffer  
246 alone were each separately fractionated by RP-HPLC and eluates collected at one  
247 minute intervals. Immunoreactive MCH, as determined by RIA, was detected in  
248 eluates collected between 19 and 28 minutes for purified MCH and eluates collected  
249 between 18 and 24 minutes for plasma (Figure 1c).

250

251 An effective range of 19.5–1248 pg MCH/ml was established and 19.5 pg/ml was  
252 taken as the level of detection. Serial dilutions of ANP,  $\alpha$ -MSH and ACTH failed to  
253 displace the MCH antibody demonstrating the specificity of the radioimmunoassay.  
254 Only supraphysiological concentrations of NEI-MCH showed any potential for cross-  
255 reactivity with the MCH antibody (at concentrations 100x greater than MCH: data not  
256 shown). Standard curves diluted in buffer or plasma (with unknown initial  
257 concentrations of MCH: data not shown) were parallel.

258

### 259 Circulating MCH in humans

260 Cross-sectional study: Demographic and anthropometric measurements of 231

261 subjects are presented in Table 1. Fasting plasma MCH concentrations were  
262 detected in the range 19.5–70.4 pg/ml with the exception of one subject who had  
263 fasting MCH concentrations in excess of 150 pg/ml (this outlier was not included in  
264 Table 1 or in the statistical analyses). Within this assay 95% of the sample  
265 population would be expected to have fasting MCH concentrations between 19.5 and  
266 55.4 pg/ml. There were no significant differences in mean fasting plasma MCH  
267 concentrations between males and females. When the sample population was  
268 grouped by gender and BMI, there were no significant differences in plasma MCH  
269 concentrations between the groups (Figure 2a) except between males with a BMI  
270 <20 compared with those with a BMI >30 ( $p<0.0473$ , ANOVA with Tukey's Multiple  
271 Comparison test). Fasting plasma MCH concentrations were not significantly  
272 correlated with percent fat mass, percent lean mass, height, weight or age. There  
273 were however significant correlations between fasting plasma MCH concentrations  
274 and: a) both body fat mass weight (kg) and BMI in females with excess fat ( $\geq 31\%$   
275 body fat) ( $n=41$ ,  $r=-0.326$ ,  $p=0.038$ ;  $n=39$ ,  $r=-0.372$ ,  $p=0.020$ , respectively); b) male  
276 BMI ( $n=96$ ,  $r=0.230$ ,  $p=0.030$ ); and c) BMI in males with excess fat ( $\geq 21\%$  body fat)  
277 ( $n=44$ ,  $r=0.513$ ,  $p<0.001$ ; Figure 2b). Note that in females the correlations were  
278 inverse whilst in males correlations were positive.

279  
280 Intervention studies: Demographic, anthropometric and fasting MCH measurements  
281 are presented in Tables 2 and 3 for Cohorts A and B, respectively. There were  
282 differences in the post-prandial plasma MCH concentrations between Cohort A  
283 ( $n=32$ ) and Cohort B ( $n=50$ ). In Cohort A, there were no differences in plasma MCH  
284 concentrations at any of the four time-points ( $p=0.772$ ; Figure 3). In Cohort B,  
285 plasma MCH concentrations increased after eating (females  $p=0.023$ , males

286 p=0.006; Figure 4).

287

288 There were no differences in circulating concentrations of glucose or insulin between  
289 males and females and no effect of % body fat in either Cohort A or Cohort B. In  
290 Cohort A, although there were no correlations with mean plasma MCH  
291 concentrations or the MCH area under the curve (AUC) and the glucose AUC, both  
292 the mean plasma MCH concentrations and the MCH AUC were correlated with the  
293 insulin AUC in all individuals (that is, both females and males) with excess fat only  
294 (that is,  $\geq 31\%$  body fat in females and  $\geq 21\%$  in males) ( $n=6$ ,  $r=0.907$ ,  $p=0.013$  and  
295  $n=6$ ,  $r=0.932$ ,  $p=0.007$ , respectively). In Cohort B, there were no significant  
296 associations between mean plasma MCH concentrations or the MCH AUC and the  
297 glucose and insulin AUCs.

298

299 Mean circulating leptin concentrations were greater in individuals with excess fat  
300 compared to lean individuals (Cohort A,  $p=0.025$ ; Cohort B,  $p>0.001$ ) and women  
301 have higher concentrations than males (Cohort A,  $p>0.001$ ; Cohort B,  $p>0.001$ ):  
302 Figures 3 and 4). In both cohorts in females, circulating leptin concentrations had  
303 decreased 1 hour post-prandial (Cohort A:  $p=0.012$ ; Cohort B:  $p=0.037$ ). In males,  
304 circulating leptin concentrations did not decrease significantly until 2 hours post-  
305 prandial in Cohort B only ( $p=0.028$ ). In Cohort A, there were no significant  
306 correlations between plasma MCH and leptin at any time-point or the MCH and leptin  
307 AUCs. In Cohort B there were three significant correlations between plasma MCH  
308 and leptin concentrations. There were negative correlations between plasma MCH  
309 concentrations and leptin concentrations in fasted males with excess fat (that is,  
310  $\geq 21\%$  body fat) ( $n=9$ ,  $r=-0.672$ ,  $p=0.047$ ) and at 30 minutes post-prandial in females

311 with excess fat (that is,  $\geq 31\%$  body fat) ( $n=8$ ,  $r=-0.757$ ,  $p=0.030$ ). By contrast, there  
312 was a positive correlation between mean plasma MCH concentrations and mean  
313 plasma leptin concentrations in lean males (that is,  $< 21\%$  body fat) ( $n=11$ ,  $r=0.654$ ,  
314  $p=0.029$ ). The MCH AUC was not significantly correlated with the leptin AUC.

315

316 In both cohorts, there were no significant correlations between fasted or mean post-  
317 prandial plasma MCH concentrations and RMR (for values, Tables 2 and 3) in either  
318 males or females or when categorized by adiposity.

319

## 320 **DISCUSSION**

321 A sensitive and specific RIA for the quantifiable measurement of MCH in human  
322 plasma has been successfully developed. To confirm that MCH is detectable and  
323 measurable in human plasma cross-validation was performed by RP-HPLC and MS.

324 A peak was detected between 21 and 28 minutes when plasma was run through the  
325 HPLC column which corresponds to the elution time of purified MCH. Additionally,  
326 when human plasma was subject to MS, product ions of identical mass to those  
327 generated by purified MCH were observed. Immunoreactive MCH was detected by  
328 RIA only in the eluates collected between 18 and 28 minutes of either purified MCH  
329 or human plasma. In the RIA, the only molecule assessed showing evidence of  
330 cross-reactivity was NEI-MCH, though only at supra-physiological concentrations.

331 Currently there is little evidence to suggest that NEI-MCH circulates therefore at  
332 physiological concentrations this assay is specific for MCH. Furthermore, parallelism  
333 of the dilution curves of plasma to the standard curve confirmed that other plasma  
334 components have no adverse effects on the curve. Plasma MCH retained stability  
335 under various conditions including freeze-thaw cycles and being left at room

336 temperature overnight. MCH was only detected in plasma collected in lithium  
337 heparin or EDTA vacutainers or in serum tubes containing a clotting agent. Other  
338 anti-coagulants interfered with detection. These results indicate that collection  
339 methods for plasma MCH should be standardized, though variability in storage  
340 conditions is not detrimental.

341

342 Using the RIA described herein, repeatable measures of the relative concentrations  
343 of MCH in circulation have been obtained. The range of values obtained do vary  
344 significantly however from the two other studies published to date (Gavrila *et al.*,  
345 2005; Schmidt *et al.*, 2015). The two other research groups used two different  
346 assays from the same commercial supplier and it is not known if the assays utilize  
347 the same antibody. Neither group appeared to validate the assay they have used  
348 within their own laboratories and there is little information supplied by the company  
349 to suggest that the assays have been validated by the company itself. Whilst it is  
350 not uncommon, as Schmidt and colleagues noted in their discussion on the  
351 differences in measurements for MCH in their studies and Gavrila and colleagues',  
352 for there to be a wide range of baseline values reported depending on the method of  
353 assaying (for example, B-type natriuretic peptide [as reviewed by Fischer *et al.*,  
354 2001] and oxytocin [as reviewed by Leng and Ludwig, 2016], the paucity of validation  
355 data available for the two commercial assays does preclude direct comparisons  
356 being made between their findings and those described herein.

357

358 Fasting blood samples from 135 females and 96 males were obtained to establish a  
359 reference range. Subjects were recruited from a range of ethnicities, ages and  
360 phenotypes. The mean fasting plasma MCH concentration was  $36.7 \pm 9.3$  pg/ml and



361 95% of the population would be expected to have plasma MCH concentrations  
362 between 19.4-55.4 pg/ml. In rodents, increased availability of hypothalamic MCH is  
363 associated with adiposity (Ludwig *et al.*, 2001; Gomori *et al.*, 2002) whilst decreased  
364 availability is associated with leanness (Marsh *et al.*, 2002; Kowalski *et al.*, 2004),  
365 therefore it was hypothesized that circulating MCH concentrations would also be  
366 aligned to fat mass in humans. Whilst there were no associations between percent  
367 fat mass, percent lean mass, age, height or weight: there were significant  
368 correlations between circulating MCH concentrations and BMI in males and females  
369 with excess fat (that is,  $\geq 31\%$  body fat in females and  $\geq 21\%$  in males). There was  
370 also a correlation between circulating MCH concentrations and body fat weight (kg)  
371 in females with excess fat. These results are curious since the correlations between  
372 BMI and MCH were inverse for women and positive for men. Hence it appears there  
373 may be some gender and age related regulation which differs in the presence of  
374 adiposity. In young males MCH may be indexed to leanness rather than adiposity  
375 since there was a positive correlation between BMI and lean body mass (kg) in the  
376 younger cohort. The two major peripheral adiposity signals; leptin and insulin are  
377 processed differently in males and females, female brains being more sensitive to  
378 leptin and male brains being more sensitive to insulin. Leptin correlates better with  
379 total body fat in females and insulin correlates better with total body fat in males  
380 (Clegg *et al.*, 2003; Woods *et al.*, 2003). It could be that MCH also displays a  
381 sexually dimorphic sensitivity: whether or not fat interferes with MCH signalling either  
382 directly or indirectly via leptin resistance or some other perturbation of the system is  
383 not currently known.  
384

385 There were no differences between male and female fasting circulating MCH  
386 concentrations. In this respect, our results agree with those of Gavrilu and  
387 colleagues (Gavrilu *et al.*, 2005). Age-related changes in body composition did not  
388 appear to impact on circulating MCH concentrations since there were no differences  
389 in circulating MCH concentrations between groups when all subjects in the cross-  
390 sectional study were categorized by gender, age ( $\leq 30$  years, 31-39 years and  $\geq 40$   
391 years) and % body fat (male lean= $<21$  %; male excess fat= $\geq 21$ %; female lean= $<31$   
392 %; female excess fat= $\geq 31$ %). Nor was there a significant correlation between age  
393 and absolute circulating MCH concentrations. However in the intervention studies  
394 an effect of age was observed, both in fasting MCH concentrations which were  
395 greater in the younger group compared to the older group and in the post-prandial  
396 response (compare Figures 3 and 4).

397

398 In the older group circulating MCH concentrations rose significantly during the 2 hour  
399 post-prandial sampling period in males and females, and in both lean individuals and  
400 those with excess fat. In the younger group, post-prandial circulating MCH  
401 concentrations did not change significantly. In both groups, post-ingestive circulating  
402 leptin concentrations declined significantly. Whether or not this was related to the  
403 meal, MCH concentrations or the morning nadir of leptin requires qualification (Sinha  
404 *et al.*, 1996). In the lipostatic model of energy homeostasis (for review see Woods,  
405 2005), leptin inhibits the anabolic pathway through which MCH operates. Leptin and  
406 MCH may also interact in the periphery; for example, the MCH receptor has been  
407 detected on rodent adipocytes (Bradley *et al.*, 2000). Whilst there is ample evidence  
408 that MCH and leptin can both inhibit and stimulate each other (Huang *et al.*, 1999;  
409 Bradley *et al.*, 2000; Kokkotou *et al.*, 2001)), few studies have attempted to evaluate

410 the association between circulating MCH and leptin. Except for in 3 small sub-groups  
411 (within Cohort B) there were no consistent significant associations between  
412 circulating MCH and leptin concentrations: in this respect our results broadly concur  
413 with Gavrilu and colleagues (2005) who found no associations with serum leptin  
414 concentrations in a younger population ( $17\pm 1.7$  yrs). Leptin action is altered with  
415 aging and is characterized by increased adiposity and the development of leptin  
416 resistance: it is not known which precedes which (Carrascosa *et al.*, 2009). In the  
417 older individuals, it may be that the differential direction of the plasma MCH/plasma  
418 leptin relationship between those with excess fat and lean phenotypes (negative  
419 *versus* positive) is symptomatic of disruption between MCH and leptin signaling, in  
420 this context it is possible that MCH may be responding to some leptin resistant state.  
421 Overall there was a trend for circulating MCH and leptin concentrations to be  
422 inversely correlated which, whilst non-significant, was consistent. This would be  
423 expected if the inhibitory effect of hypothalamic leptin on hypothalamic MCH is  
424 reflected in the periphery.

425

426 MCH has been shown to stimulate insulin release from beta cells *in vitro* and it has  
427 been suggested that MCH may be necessary for normal  $\beta$ -cell function (Pissios *et al.*,  
428 2007). Whether or not MCH acts in a paracrine or autocrine manner within the  
429 pancreas or is released into the circulation is not known. If MCH is active at the level  
430 of the endocrine pancreas it was hypothesised that the post-prandial insulin  
431 response might be related to the post-prandial MCH response and could be altered  
432 in the presence of insulin resistance. Whilst there was a gender difference in the  
433 magnitude of the AUC insulin, which did not appear to be related to adiposity, our  
434 results indicate that there were no robust associations between the MCH AUC or

435 mean circulating MCH concentrations and the glucose or insulin AUCs. However in  
436 the younger cohort, there was a significant positive relationship between the  
437 respective AUCs for insulin and MCH, and with the insulin AUC and mean circulating  
438 MCH concentrations but only in individuals with excess fat. Whilst in this group it  
439 would seem that the MCH and insulin response to food stimuli moves in the same  
440 direction, the small sample size of these sub-groups precludes broader application  
441 and a larger scale enquiry should be undertaken.

442

443 At the outset of the intervention study with Cohort B, it was the intention to compare  
444 an older cohort with excess fat with an older leaner cohort reasoning that the more  
445 corpulent group would be more likely to have some degree of insulin resistance.  
446 However even those displaying morphological characteristics which would incline  
447 them towards insulin resistance; that is a BMI of  $> 30 \text{ kg/m}^2$  and waist-hip ratio of  $>$   
448 1.0 for men and  $> 0.8$  for women, had fasting and 2 hour post-prandial blood glucose  
449 concentrations within the normal range ( $< 6.1 \text{ mmol/l}$  fasting,  $< 7.8 \text{ mmol/l}$  2 hrs post-  
450 prandial). Furthermore the individual Homeostatic Model Assessment (HOMA)  
451 scores (Matthews *et al.*, 1985), which is a mathematical model method for detecting  
452 insulin resistance, only exceeded 2.0 in 2 individuals (data not shown). There  
453 appears to be no reference values for HOMA scores which represent insulin  
454 resistance, however scores in excess of 2.00 and 3.99 have been taken as definitive  
455 in other studies (Bakari and Onyemelukwe, 2005; Wahreneburg *et al.*, 2005).  
456 Plasma insulin concentrations were not significantly different between those with  
457 excess fat and lean individuals at any time point and the AUCs for insulin and  
458 glucose were not different between the excess fat and lean groups of either gender.  
459 Therefore it would seem that glucose homeostasis was still normal in both the lean

460 group and the excess fat group, hence the hypothesis that an altered MCH response  
461 may have been observed in the presence of insulin resistance could not be further  
462 explored in the current study. The effect of insulin resistance on circulating MCH  
463 concentrations therefore requires further investigation.

464

465 Contrary to rodent studies, in humans there is little evidence to support a role for  
466 circulating MCH in energy homeostasis, therefore it was deemed important to  
467 describe associations between RMR and circulating MCH concentrations in young  
468 healthy and older individuals. We found no evidence of a relationship between  
469 fasted or fed plasma MCH concentrations and RMR in either group. To further  
470 explore the relationship between metabolic rate and circulating MCH regression  
471 analyses were performed. Results indicate that factors associated with variance in  
472 RMR, that is percent fat-free mass, percent fat-mass, fat-free mass (kg) and gender,  
473 as well as RMR *per se* do not contribute significantly to the variance in fasted or  
474 post-prandial MCH concentrations. These results suggest that circulating MCH  
475 cannot be considered a biomarker of resting energy expenditure in humans.

476

477 In conclusion, we have demonstrated that circulating MCH can be reliably and  
478 quantifiably measured in humans by RIA. Overall circulating MCH concentrations  
479 are not overtly reactive and no robust physiological effects of circulating MCH were  
480 observed. There does however appear to be some differential regulation in the  
481 presence of a combination of gender and adiposity which is variable depending on  
482 the population under examination. Hence, in the subjects studied here circulating  
483 MCH is not a marker of energy homeostasis, contrary to the suggestion of Gavrilu  
484 and colleagues (2005). Rather our results suggest that circulating MCH may not

485 have a signalling role in this context although a detailed 24 hour profile of circulating  
486 MCH should be established which would lend contextual relevance to the limited  
487 body of knowledge regarding circulating MCH in humans to date.

488

489 DECLARATION OF INTEREST: There is no conflict of interest that could be  
490 perceived as prejudicing the impartiality of the research reported.

491 GRANTS AND FELLOWSHIPS: JN was in receipt of a University of Westminster,  
492 School of Life Sciences PhD scholarship

493 AUTHOR CONTRIBUTIONS: J.N., F.A., M.FB., B.D., A.C and J.F.M. planned the  
494 research; J.N., F.A., M.FB. and B.D. recruited subjects and collected samples; J.N.,  
495 F.A., M.FB., B.D. and T.V. did the laboratory analyses; J.N. did the statistical  
496 analyses; and J.N., A.C. and J.F.M. wrote the manuscript. All authors read and  
497 approved the final version of the manuscript.

498

499 ACKNOWLEDGEMENTS: The authors would like to thank Carole Seaward,  
500 Laboratory Technician for her help with data collection, particularly her venepuncture  
501 skills.

502

503 **REFERENCES**

- 504 American College of Sports Medicine (ACSM) 1996 Based on information from the  
505 American College of Sports Medicine and The American Council on Exercise. In:  
506 *Exercise Physiology*, edn 4, Eds WD McArdle, FI Katch & VL Katch VL. USA:  
507 Lippincott, Williams and Wilkins.
- 508 Bakari AG & Onyemelukwe GC 2005 Insulin resistance in type 2 diabetic Nigerians.  
509 *International Journal of Diabetes and Metabolism* **13** 24 - 27
- 510 Baker BI, Bird DJ & Buckingham JC 1985 Salmonid melanin concentrating hormone  
511 inhibits corticotrophin release. *Journal of Endocrinology* **106** R5-R8.
- 512 Barber LD, Baker BI, Penny JC & Eberle AN 1987 Melanin concentrating hormone  
513 inhibits the release of  $\alpha$ -MSH from teleost pituitary glands. *General and Comparative*  
514 *Endocrinology* **65** 79-86.
- 515 Bittencourt JC 2011 Anatomical organisation of the melanin-concentrating hormone  
516 peptide family in the mammalian brain. *General and Comparative Endocrinology* **172**  
517 185–197.
- 518 Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon JL, Vale W &  
519 Sawchenko PE 1992 The melanin-concentrating hormone system of the rat brain: an  
520 immuno- and hybridization histochemical characterization. *Journal of Comparative*  
521 *Neurology* **319** 218-245.
- 522 Bjursell M, Gerdin A-K, Ploj K, Svensson, D, Svennson L, Oscarsson J, Snaith M,  
523 Tornell J & Bohlooly-Y M 2006 Melanin-concentrating hormone receptor 1 deficiency  
524 increases insulin sensitivity in obese leptin-deficient mice without affecting body  
525 weight. *Diabetes* **55** 725–733.

- 526 Bradley RL, Kokkotou EG, Maratos-Flier E & Cheatham B 2000 Melanin-  
527 concentrating hormone regulates leptin synthesis and secretion in rat adipocytes.  
528 *Diabetes* **49** 1073-1077.
- 529 Carrascosa JM, Ros M, Andres A, Fernandez-Agullo T & Arribas C 2009 Changes in  
530 the neuroendocrine control of energy homeostasis by adiposity signals during aging.  
531 *Experimental Gerontology* **44** 20-25.
- 532 Clegg DJ, Riedy CA, Smith KA, Benoit SC & Woods SC 2003 Differential sensitivity  
533 to central leptin and insulin in male and female rats. *Diabetes* **52** 682-687.
- 534 Fischer Y, Filzmaier K, Stiegler H, Graf J, Fuhs S, Franke A, Janssens U & Gressner  
535 AM 2001 Evaluation of a new, rapid bedside test for quantitative determination of B-  
536 type natriuretic peptide. *Clinical Chemistry* **47** 591 - 594
- 537 Fleisch A 1951 Le metabolisme basal standard et sa determination au moyen du  
538 "Metabocalculator". *Helvetica Medica Acta* **1** 23-44.
- 539 Gavrilu A, Chan JL, Miller LC, Heist K, Yannakouris N & Mantzoros CS 2005  
540 Circulating melanin-concentrating hormone, agouti-related protein, and alpha-  
541 melanocyte-stimulating hormone levels in relation to body composition: alterations in  
542 response to food deprivation and recombinant human leptin administration. *Journal*  
543 *of Clinical Endocrinology and Metabolism* **90** 1047-1054.
- 544 Gomori A, Ishihara A, Ito M, Mashiko S, Matsushita H, Yumoto M, Ito M, Tanaka T,  
545 Tokita S, Moriya M *et al.* 2002 Chronic intracerebroventricular infusion of MCH  
546 causes obesity in mice. *American Journal of Physiology, Endocrinology and*  
547 *Metabolism* **284** E583–E588.
- 548 Hervieu G & Nahon JL 1995 Pro-melanin concentrating hormone messenger  
549 ribonucleic acid and peptides expression in peripheral tissues of the rat.  
550 *Neuroendocrinology* **61** 348-364.



- 551 Hervieu G, Volant K, Grishina O, Descroix-Vagne M & Nahon JL 1996 Similarities in  
552 cellular expression and functions of melanin-concentrating hormone and atrial  
553 natriuretic factor in the rat digestive tract. *Endocrinology* **137** 561-571.
- 554 Huang Q, Viale A, Picard F, Nahon J-L & Richard D 1999 Effects of leptin on  
555 melanin-concentrating hormone expression in the brain of lean and obese  
556 lepob/lepob mice. *Neuroendocrinology* **69** 145-153.
- 557 Kokkotou E, Tritos NA, Mastaitis JW, Sliker L & Maratos-Flier E 2001 Melanin-  
558 concentrating hormone receptor is a target of leptin action in the mouse brain.  
559 *Endocrinology* **142** 680–686.
- 560 Kowalski TJ, Farley C, Cohen-Williams ME, Varty G & Spar BD 2004 Melanin-  
561 concentrating hormone-1 receptor antagonism decreases feeding by reducing meal  
562 size. *European Journal of Pharmacology* **497** 41-47.
- 563 Leng G & Ludwig M 2016 Intranasal oxytocin: Myths and delusions. *Biological*  
564 *Psychiatry* **79** 243 - 250
- 565 Ludwig DS, Mountjoy KG, Tatro JB, Gillette JA, Frederick RC, Flier JS & Maratos-  
566 Flier E 1998 Melanin-concentrating hormone: a functional melanocortin antagonist in  
567 the hypothalamus. *American Journal of Physiology* **274** E627-633.
- 568 Ludwig DS, Tritos N.A, Mastaitis JW, Kulkarni R, Kokkotou E, Elmquist J, Lowell B,  
569 Flier JS & Maratos-Flier E 2001 Melanin-concentrating hormone overexpression in  
570 transgenic mice leads to obesity and insulin resistance. *Journal of Clinical*  
571 *Investigation* **107** 379–386.
- 572 Mantzoros C 2005 Authors' response re: melanin-concentrating hormone and energy  
573 balance. *Journal of Clinical Endocrinology and Metabolism* **90** 6337.
- 574 Marsh DJ, Weingarh DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, Guan XM,  
575 Jiang MM, Feng Y, Camacho RE *et al.* 2002 Melanin-concentrating hormone-1

576 deficient mice are lean, hyperactive and hyperphagic and have altered metabolism.  
577 *Proceedings of the National Academy of Sciences, USA* **99** 3240–3245.

578 Mashiko S, Ishihara A, Gomori A, Moriya M, Ito M, Iwaasa H, Matsuda M, Feng Y,  
579 Shen Z, Marsh DJ *et al.* 2005 Antiobesity effect of a melanin-concentrating hormone  
580 1 receptor antagonist in diet-induced obese mice. *Endocrinology* **146** 3080–3086.

581 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC 1985  
582 Homeostasis model assessment: insulin resistance and  $\beta$ -cell function from fasting  
583 plasma glucose and insulin concentrations in man. *Diabetologica*, **28** 412 - 419

584 Maulon-Feraille L, Della Zuana O, Suply T, Rovere-Jovene C, Audinot V, Levens N,  
585 Boutin JA, Duhault J & Nahon JL 2002 Appetite-boosting property of pro-melanin-  
586 concentrating hormone(131-165) (neuropeptide-glutamic acid-isoleucine) is  
587 associated with proteolytic resistance. *Journal of Pharmacology and Experimental*  
588 *Therapeutics* **302** 766-773.

589 McArdle WD, Katch FI & Katch VL 2001 Exercise Physiology. edn 5, pp 191. Ed P  
590 Darcy. USA: Lippincott, Williams and Wilkins.

591 Pereira-da-Silva M, De Souza CT, Gasparetti AL, Saad MJ & Velloso LA 2005  
592 Melanin-concentrating hormone induces insulin resistance through a mechanism  
593 independent of body weight gain. *Journal of Endocrinology* **186** 193-201.

594 Pissios P, Ozcan U, Kokkotou E, Okada T, Liew CW, Liu S, Peters JN, Dahlgren G,  
595 Karamchandani J, Kudva YC *et al.* 2007 Melanin concentrating hormone is a novel  
596 regulator of islet function and growth. *Diabetes* **56** 311-319.

597 Qu D, Ludwig DS, Gammeltoft S, Piper M, Pellemounter MA, Cullen MJ, Mathes  
598 WF, Przypek R, Kanarek R & Maratos-Flier E 1996 A role for melanin-concentrating  
599 hormone in the central regulation of feeding behaviour. *Nature* 380 243–247.

- 600 Schmidt FM, Nowak C, Kratzsch J, Sander C, Hegerl U & Schönknecht P 2015  
601 Dynamics of melanin-concentrating hormone (MCH) serum levels in major  
602 depressive disorder during antidepressant treatment. *Journal of Affective Disorders*  
603 **180** 207-213.
- 604 Sandig H, McDonald J, Gilmour J, Arno M, Lee TH & Cousins DJ 2007 Human Th2  
605 cells selectively express the orexigenic peptide, pro-melanin-concentrating hormone.  
606 *Proceedings of the National Academy of Sciences, USA* **104** 12440-12444.
- 607 Santollo J & Eckel LA 2008 The orexigenic effect of melanin-concentrating hormone  
608 (MCH) is influenced by sex and stage of estrous cycle. *Physiology and Behaviour*  
609 **93** 842–850.
- 610 Segal-Lieberman G, Bradley RL, Kokkotou E, Carlson M, Trombly DJ, Wang X, Bats  
611 S, Myers MG, Flier JS & Maratos-Flier E 2003 Melanin-concentrating hormone is a  
612 critical mediator of the leptin-deficient phenotype. *Proceedings of the National*  
613 *Academy of Sciences, USA* **100** 10085-10090.
- 614 Shimada M, Tritos NA, Lowell BB, Flier JS & Maratos-Flier E 1998 Mice lacking  
615 melanin-concentrating hormone are hypophagic and lean. *Nature* **396** 670–674.
- 616 Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S,  
617 Marco C & Caro JF 1996 Nocturnal rise of leptin in lean, obese, and non-insulin-  
618 dependent diabetes mellitus subjects. *Journal of Clinical Investigation* **97** 1344-  
619 1347.
- 620 Sita LV, Elias CF & Bittencourt JC 2007 Connectivity pattern suggests that incerto-  
621 hypothalamic area belongs to the medial hypothalamic system. *Neuroscience* **148**  
622 949–969.

- 623 Stricker-Krongrad A, Dimitrov T & Beck B 2001 Central and peripheral dysregulation  
624 of melanin-concentrating hormone in obese Zucker rats. *Brain Research Molecular*  
625 *Brain Research* **92** 43-48.
- 626 Sun G, Tian Z, Murata T, Narita K, Honda K & Higuchi T 2004 Central and peripheral  
627 immunoreactivity of melanin-concentrating hormone in hypothalamic obese and  
628 lactating rats. *Journal of Neuroendocrinology* **16** 79–83.
- 629 Verlaet M, Adamantidis A, Coumans B, Chanas G, Zorzi W, Heinen E, Grisar T &  
630 Lakaye B 2002 Human immune cells express ppMCH mRNA and functional MCHR1  
631 receptor. *FEBS Letters* **527** 205-210.
- 632 Wahrenburg H, Hertel K, Leijonhufvud B-M, Persson L-G, Toft E & Arner P 2005 Use  
633 of waist circumference to predict insulin resistance: retrospective study. *British*  
634 *Medical Journal* **330** 1363 – 1364
- 635 Waters SM & Krause JE 2005 Letter re: melanin-concentrating hormone and energy  
636 balance. *Journal of Clinical Endocrinology and Metabolism* **90** 6337.
- 637 Woods SC 2005 Signals that influence food intake and body weight. *Physiology and*  
638 *Behaviour* **86** 709-716.
- 639 Woods SC, Gotoh K & Clegg DJ 2003 Gender differences in the control of energy  
640 homeostasis. *Experimental Biology and Medicine* **228** 1175-1180.
- 641
- 642
- 643
- 644